Palo Alto Investors LLC Has $4,766,000 Stake in Sunesis Pharmaceuticals, Inc. (SNSS)

Palo Alto Investors LLC held its position in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,162,473 shares of the biopharmaceutical company’s stock at the end of the first quarter. Sunesis Pharmaceuticals makes up about 0.2% of Palo Alto Investors LLC’s investment portfolio, making the stock its 26th largest position. Palo Alto Investors LLC owned 5.56% of Sunesis Pharmaceuticals worth $4,766,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in Sunesis Pharmaceuticals by 1.1% in the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 1,230 shares during the period. Morgan Stanley raised its position in Sunesis Pharmaceuticals by 768.1% in the first quarter. Morgan Stanley now owns 34,080 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 30,154 shares during the period. Geode Capital Management LLC raised its position in Sunesis Pharmaceuticals by 9.8% in the first quarter. Geode Capital Management LLC now owns 62,353 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 5,571 shares during the period. Vanguard Group Inc. raised its position in Sunesis Pharmaceuticals by 35.0% in the first quarter. Vanguard Group Inc. now owns 581,940 shares of the biopharmaceutical company’s stock worth $2,386,000 after buying an additional 150,994 shares during the period. Finally, Neuberger Berman Group LLC raised its position in Sunesis Pharmaceuticals by 16.6% in the first quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 20,000 shares during the period. 55.34% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ SNSS) traded up 1.79% during mid-day trading on Tuesday, hitting $2.85. 58,277 shares of the stock traded hands. Sunesis Pharmaceuticals, Inc. has a 1-year low of $2.73 and a 1-year high of $6.30. The company’s market capitalization is $61.16 million. The company’s 50-day moving average price is $3.07 and its 200 day moving average price is $3.74.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.83) by $0.36. The business had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $1.57 million. During the same period last year, the firm posted ($0.12) EPS. Sunesis Pharmaceuticals’s quarterly revenue was up 4.7% compared to the same quarter last year. Equities research analysts forecast that Sunesis Pharmaceuticals, Inc. will post ($2.08) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/06/20/palo-alto-investors-llc-has-4766000-stake-in-sunesis-pharmaceuticals-inc-snss.html.

A number of research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 15th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research note on Tuesday, May 2nd.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply